Purdue Pharma Bankruptcy Plan: A Step Towards Opioid Justice?

On November fourteenth, a pivotal moment unfolds in the legal battle against Purdue Pharma, the maker of OxyContin. Lawyers representing various groups, including cities, states, and individuals affected by addiction, urge a bankruptcy court judge to approve a plan to settle thousands of opioid-related lawsuits against the company. This decision could bring a long chapter to a close in the efforts to hold Purdue Pharma accountable for its role in the opioid crisis, which has been linked to hundreds of thousands of deaths since nineteen ninety-nine. The company filed for bankruptcy protection six years ago, facing lawsuits with claims that grew to trillions of dollars. This week, closing arguments were heard in a three-day hearing about the proposed bankruptcy plan. The entire process has been filled with strong emotions and disagreements among the many parties who took Purdue to court, highlighting the complex balance between seeking justice and the practical realities of bankruptcy law. The Sackler family, who own Purdue, would pay up to seven billion dollars and give up ownership of Purdue Pharma. The company would also change its name, and its future profits would be dedicated to fighting the opioid crisis. Certain Sackler family members would be barred from involvement in companies selling opioids in other countries and from having their names on institutions in exchange for donations. Company documents, many of which would normally be private, are to be made public. While most of the money will go to state and local governments to combat the epidemic, individuals harmed by Purdues products will also receive some funds, a unique aspect compared to other major opioid settlements. The Daily News Now! - Every city. Every story. AI Powered. Hosted on Acast. See acast.com/privacy for more information.